KPT-330 - CAS# 1393477-72-9 Catalog No.:M6605-10 MM-102 was suggested to be

MM-102 was suggested to be used at 10-100 µM final concentration in vitro and in cellular assays

and improves glycaemic control

Epub 2011 Jun 13

Ba/F3 cells harboring native or T315I mutated Bcr-Abl constructs were treated with GNF-2 and AKIs

Molecular Weight: 443

KPT-330 - CAS# 1393477-72-9 Catalog No.:M6605-10 MM-102 was suggested to beKPT 330, CAS No. 1393477 72 9, is an orally bioavailable, potent and selective XPO1 CRM1 Inhibitor. KPT 330 is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia. KPT 330 potentiates the antitumor activity of gemcitabine in human pancreatic cancer through inhibition of tumor growth, depletion of the antiapoptotic proteins, and induction of apoptosis. KPT 330 has strong activity against primary